|
|
PLoS ONE. 2007; 2(4): e392. Published online 2007 April 25. doi: 10.1371/journal.pone.0000392. | PMCID: PMC1849966 |
Copyright Nawroth et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Extracellular Sulfatases, Elements of the Wnt Signaling Pathway, Positively Regulate Growth and Tumorigenicity of Human Pancreatic Cancer Cells Roman Nawroth,1¤ Annemieke van Zante,2 Sara Cervantes,3 Michael McManus,3 Matthias Hebrok,3,4 and Steven D. Rosen1,4* 1Department of Anatomy, University of California San Francisco, San Francisco, California, United States of America 2Department of Pathology, University of California San Francisco, San Francisco, California, United States of America 3Diabetes Center, University of California San Francisco, San Francisco, California, United States of America 4Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, United States of America Mikhail Blagosklonny, Academic Editor Ordway Research Institute, Inc., United States of America Received March 18, 2007; Accepted March 28, 2007. Background Heparan sulfate proteoglycans (HSPGs) are control elements in Wnt signaling, which bind extracellularly to Wnt ligands and regulate their ability to interact with signal transduction receptors on the cell surface. Sulf-1 and Sulf-2 are novel extracellular sulfatases that act on internal glucosamine-6-sulfate (6S) modifications within HSPGs and thereby modulate HSPG interactions with various signaling molecules, including Wnt ligands. Emerging evidence indicates the importance of reactivated Wnt signaling in a number of cancers, including pancreatic adenocarcinoma. Principle Findings Both Sulf proteins were upregulated in human pancreatic adenocarcinoma tumors and were broadly expressed in human pancreatic adenocarcinoma cell lines. Expression of human extracellular sulfatases Sulf-1 and Sulf-2 enhanced Wnt signaling in a reconstituted system. Three of four pancreatic adenocarcinoma cell lines tested exhibited autocrine Wnt signaling, in that extracellular Wnt ligands were required to initiate downstream Wnt signaling. Exposure of these pancreatic adenocarcinoma cells to a catalytically inactive form of Sulf-2 or siRNA-mediated silencing of endogenous Sulf-2 inhibited both Wnt signaling and cell growth. Sulf-2 silencing in two of these lines resulted in markedly reduced tumorigenesis in immunocompromised mice. Conclusions/Significance We have identified the Sulfs as potentiators of autocrine Wnt signaling in pancreatic cancer cells and have demonstrated their contribution to the growth and tumorigenicity of these cells. Since the Sulfs are extracellular enzymes, they would be attractive targets for therapy of pancreatic cancer. Our results run counter to the prevailing view in the literature that the Sulfs are negative regulators of tumorigenesis. Pancreatic adenocarcinoma is the most common form of pancreatic cancer and one of the most deadly malignancies with a 5 year survival rate of 3% and a median survival of less than 6 months [1]. There has been recent interest in the role of embryonic signaling pathways in cancer. Considerable evidence has demonstrated that these pathways remain functional in a limited number of cells within the adult and that dysregulation of these pathways contributes to the formation and persistence of tumors [2], [3]. In this regard, the reactivation of Notch, Hedgehog and Wnt pathways have attracted recent interest in cancers of the GI tract, including pancreatic adenocarcinoma [2], [4], [5]. The dysregulation of Wnt signaling in pancreatic adenocarcinoma is the focus of the present study. Wnts comprise a large family of secreted proteins, which regulate cell growth, apoptosis, motility and differentiation during embryonic development [3]. In brief, activation of the canonical Wnt pathway is initiated by binding of Wnt ligands to signal transduction receptors on the cell surface, which leads to the accumulation of non-phosphorylated β-catenin in the cytoplasm. After its translocation to the nucleus, β-catenin forms a complex with members of the TCF/LEF family of transcription factors, and activates target genes [3]. Wnt signaling was first implicated in cancer through the analysis of mammary gland tumorigenesis induced by the mouse mammary tumor virus (MMTV) [6]. A high proportion of the tumors were due to activation of Wnt1 expression through insertion of the MMTV provirus into the wnt1 gene. Tumorigenesis is thought to be based on an autocrine Wnt transforming pathway in which Wnt ligand expression by mammary epithelial cells provides a growth stimulus to the same cells. Recently autocrine Wnt signaling was demonstrated in breast cancer, ovarian cancer and myeloma cell lines, [7], [8]. This mechanism, in which extracellular Wnt ligands provide an essential stimulus for cell proliferation, is distinct from that commonly found in human colon cancer and several other forms of cancer, in which constitutive activation of Wnt signaling is a consequence of mutations in downstream cytoplasmic elements such as APC, CTNN1 (encoding β-catenin) or AXIN2 [3]. These characteristic mutations in downstream Wnt signaling molecules are very rare in pancreatic adenocarcinoma [9]. Yet, aberrant activation of Wnt signaling is a significant feature of human pancreatic adenocarcinoma, as revealed by the nuclear localization of β-catenin in a significant fraction (30–65%) of tumors [9], [10]. Consistent with the histochemical evidence, biochemical analysis has established a marked elevation of total β-catenin and its increased nuclear localization in two-thirds of pancreatic adenocarcinomas [9]. Moreover, in mechanistic studies with pancreatic adenocarcinoma cell lines, inhibition of Wnt signaling resulted in reduced cell proliferation and survival in vitro [11]. An area of current interest are the extracellular regulatory elements in the Wnt signaling pathway. Among these are secreted Wnt antagonists such as Frizzled related proteins (sFRP), Wnt inhibitory factor (WIF) and the Dickkopf family (DKK) [12]. Downregulation of any of these antagonists initiates Wnt activation and contributes to several forms of cancer [12]. A class of extracellular proteins that positively regulates Wnt activity are heparan sulfate proteoglycans (HSPGs). Glypicans, for example, are required for Wnt signaling during development in Drosophila and vertebrates [13]. HSPGs are also necessary in examples of Wnt-dependent tumor formation [14], [15]. The myriad functions of HSPGs in growth and differentiation of cells [16] are mediated through their ability to bind to a diverse repertoire of growth factors and morphogens. Binding depends on the sulfation pattern of glucosamine (N-, 3-O, and 6-O positions) and uronic acid (2-O-position) within the attached heparan sulfate chains. [16]. 6-O-sulfation (6S) of glucosamine is of particular importance in the binding of many important ligands to HPSGs, including the Wnts [17]– [19]. A newly appreciated mechanism for regulating signaling by these ligands is by post-synthetic “editing” of the 6S pattern of HSPGs through the action of a class of extracellular sulfatases known as the Sulfs [20]. QSulf-1, the first member of the Sulf family to be described, was discovered in an analysis of muscle development in the quail embryo [20]. This was followed by the description of its orthologues in rat [21], mouse, and human [22] and the discovery of the closely-related homologue, Sulf-2 [22]. The Sulfs are neutral pH optimum endosulfatases that remove 6-O-sulfate from internal glucosamine residues in highly sulfated subdomains of heparin/HSPGs [18], [19], [22], [23]. The initial studies of QSulf-1 revealed a positive role in the regulation of Wnt signaling during muscle specification in the quail embryo [20]. This activity depends on the ability of QSulf-1 to reduce the interaction of Wnt ligands with HSPGs. The authors proposed a two state model in which HS chains form a high affinity HS-Wnt complex, which sequesters Wnt from interacting with its signal transduction receptors. The affinity of Wnt for HS is weakened when QSulf-1 modifies the 6S pattern of the HS chains, allowing the initiation of Wnt signaling [19]. Sulf-dependent promotion of Wnt signaling has also been observed in other developmental events [24]. In vitro evidence suggests that the Sulfs can promote other signaling pathways including angiogenesis and BMP signaling [23], [25]. Importantly, sulf null mice show reduced body mass [26], [27]. This phenotype is consistent with positive regulatory roles for the Sulfs during normal development. The discovery that canonical Wnt signaling is activated in pancreatic adenocarcinoma (see above) has focused our attention on the possible involvement of the Sulfs in this cancer. In the present study, we demonstrate upregulation of both Sulf proteins in pancreatic adenocarcinoma tumors. Using human pancreatic adenocarcinoma cancer cell lines, we establish a role for Sulf-2 in promoting autocrine Wnt signaling, in vitro cell growth and tumorigenicity. This positive contribution of a Sulf to Wnt-dependent tumor growth is in striking contrast to several reports in which the enforced expression of Sulfs antagonizes other signaling pathways (e.g. FGF-2, and HGF) in tumor cells and suppresses cell growth [28]– [34]. Sulf-1 and Sulf-2 are upregulated in human pancreatic cancer Mining of public DNA microarray datasets and a quantitative PCR study establish that SULF1 transcripts are upregulated in human pancreatic cancer ( Table 1). The latter study found that the mean level of SULF1 mRNA was 22.5-fold greater in the cancer tissue (n  = 31) than in normal pancreas (n = 19) [31]. In situ hybridization localized expression of SULF1 to tubular structures, likely representing invasive carcinoma. | Table 1SULF1 mRNA expression in human pancreatic cancers |
To determine if Sulf proteins were expressed by pancreatic adenocarcinoma in surgical specimens, we stained sections from seven archived cases with Sulf-1 and Sulf-2 antibodies and an IgG control (). Benign interlobular ducts on the same tissue sections as the invasive carcinoma served as an internal control. In 7/7 cases, the malignant epithelial cells generally showed moderate to strong staining for Sulf-1 (). For Sulf-2, 4/7 cases showed strong staining of these cells, 2/7 cases had moderate staining and 1 case was negative. Most benign ducts showed no staining or only trace staining for Sulf-1 (≈54%) or Sulf-2 (≈88%). Focal staining for Sulf-1 or Sulf-2 was seen in a minority of the benign ducts. Diffuse weak staining of fibroblasts for both Sulfs was observed in some areas of stroma, usually in association with inflammatory cells. There was no staining with the IgG control. Next, we determined expression of the Sulfs in human pancreatic adenocarcinoma cell lines by using RT-PCR to survey a panel of 24 cell lines. These were derived from either primary or metastatic pancreatic adenocarcinomas [5]. SULF1 transcripts were detected by RT-PCR in 12/24 and SULF2 transcripts in 21/24 of these lines (). To examine expression at the protein level, we investigated 4 of these cell lines, 3 of which were positive for both SULF transcripts (CFPAC-1, HS766T, L3.6sl) and 1 which was positive for only SULF2 (BxPC-3). We performed immunoblots on detergent lysates and conditioned medium (CM) derived from these cells (). Sulf-1 protein was detected in only one cell line (HS766T cells), whereas Sulf-2 protein was present in all 4. In detergent lysates, the molecular weight of the major species was 130 kDa, which corresponds to an unprocessed form for both proteins [22]. Sulf-2 protein was released into CM by all 4 cell lines. In contrast, Sulf-1 was not detected in HS766T CM. As previously observed for several breast carcinoma cell lines [25], Sulf-2 protein was detected in CM as a processed 75 kDa component. Sulf-1 and Sulf-2 promote Wnt signaling QSulf-1 has been shown to promote activation of Wnt signaling pathways in response to exogenous Wnt ligands [20]. We chose to study the effects of the human Sulfs on Wnt signaling in a similar reconstituted system [20]. We overexpressed the Sulfs in HEK 293T and co-cultured these cells with fibroblasts that expressed either Wnt1 or Wnt4. Wnt signaling activity was measured by the TCF-luciferase reporter system (TOPflash/FOPflash), a standard method for measuring β-catenin-dependent transcriptional activation [20]. Expression of each Sulf augmented Wnt signaling in response to either Wnt ligand, whereas mock-transfected HEK 293T cells did not respond (supplementary figure, Fig. S1). Thus, both HSulfs, like QSulf-1 [20], can promote Wnt signaling. Expression of sFRP-2 inhibits Wnt signaling in pancreatic adenocarcinoma cell lines Previous work has established active Wnt signaling within a series of the pancreatic adenocarcinoma cell lines, including the 4 lines above [M. Pasca di Magliano and M. Hebrok, unpublished observations]. To determine whether Wnt signaling in these 4 lines was autocrine in nature, we employed secreted Frizzled-related protein-2 (sFRP-2) as an extracellular Wnt antagonist [35], [36]. We transiently transfected the cell lines with a cDNA for sFRP-2 or with the empty vector (ctrl) and measured Wnt activity by the TCF-luciferase reporter assay. sFRP-2 expression diminished Wnt signaling ≈60% in 3 of the lines but had no effect on CFPAC-1 cells (). These results establish that the BxPC-3, HS766T and L3.6sl cells possess an autocrine Wnt signaling pathway. Catalytically inactive human sulfatase protein inhibits Wnt signaling and cell growth We next asked if the endogenous Sulfs in these cell lines were directly involved in Wnt signaling. When we overexpressed the Sulfs, there was no effect on Wnt signaling (data not shown). Since all of these cells expressed significant levels of the Sulfs, we next asked whether there might be inhibitory effects if we expressed catalytically inactive forms of these proteins. We have previously shown that mutation of two cysteines in the sulfatase domain of each Sulf eliminated sulfatase activity [22]. We transfected a cDNA encoding inactive Sulf-1 (S1ΔCC), Sulf-2 (S2ΔCC) or empty vector (ctrl) into each of the 4 cell lines and again measured Wnt activity. As shown in , expression of either inactive Sulf inhibited Wnt activity ≈50% in all but CFPAC-1 cells. The 3 responding lines were the same that exhibited autocrine Wnt signaling (). The fact that either inactive Sulf exerted equivalent effects on these pancreatic cancer cell lines suggests functional redundancy of the two enzymes. We next asked whether the exogenous addition of catalytically inactive Sulf protein would also interfere with Wnt signaling. As a source of Sulf-2 protein, we used HEK 293T cells which were stably transfected either with wild-type human Sulf-2 (S2) or catalytically inactivated Sulf-2 (S2ΔCC) [25]. We also used the parental HEK 293T cells (293T) as controls. The stable transfectants secreted the active and inactive Sulfs at comparable levels (data not shown). We incubated the pancreatic adenocarcinoma cells for 16 hours with CM from these cells or with control medium and compared Wnt signaling. Exposure to the inactive Sulf-2 protein (S2ΔCC) inhibited Wnt signaling in the same 3 cell lines that were responsive to transfection with the S2ΔCC cDNA (), whereas CFPAC cells did not show an effect. The addition of medium, conditioned with active Sulf-2 protein, did not promote Wnt signaling over the basal level. Next, we set up a co-culture system to examine the effects of recombinant Sulf protein on cell growth of the same cell lines. The pancreatic cancer cells were seeded at low density on transwell filters above feeder layers, which consisted of parental HEK 293T cells or HEK 293T expressing active or inactive Sulf-2. Cell counts were monitored for the next several days. The results paralleled the suppressive effect we observed on Wnt signaling. Thus, as compared to control medium, S2ΔCC CM inhibited the growth of BxPC-3, HS766T and L3.6sl cells () but had no effect on CFPAC-1 cells. In contrast, active Sulf-2 did not promote or inhibit cell growth of any of the lines. Lentiviral shRNA silencing of Sulf-2 in pancreatic adenocarcinoma cells reduces Wnt signaling, cell proliferation, and cell survival To further investigate the role of Sulf-2 in Wnt signaling and cell growth, we used shRNA methodology to silence the expression of Sulf-2 in these cells. We employed three shRNA constructs: two independent constructs targeting Sulf-2 (1413 and 1143) and a control (ctrl). These constructs were used in different vector backgrounds in which the presence or absence of GFP allowed us to monitor expression of the shRNAs (see MATERIALS AND METHODS). Transduced cells were sorted for GFP expression and subsequently analyzed for Sulf-2 expression. The 1143 and 1413 constructs (pLV-1143, pLV-1413) produced 80% and 90% reductions of Sulf-2 protein, respectively, in L3.6sl cells, relative to the control shRNA (pLV-ctrl) (). There was no reduction of the protein in the pLV-ctrl treated cells relative to untreated cells (data not shown). The pLV-1413 construct produced a similar reduction in BxPC3 cells in two different vector backgrounds (pLV and pSico). Inactivation of Wnt signaling results in decreased levels of activated β-catenin (N-terminally non-phosphorylated) in the nucleus [3]. We therefore isolated the nuclear fraction of Sulf-2 silenced and control cells (BxPC-3 and L3.6sl) and analyzed levels of activated β-catenin. There was a ≈80% decrease of β-catenin in Sulf-2 silenced BxPC-3 cells, and a ≈30% reduction in L3.6sl cells (). We also quantified Wnt activity using the TCF-luciferase reporter system. Consistent with the β-catenin result, this assay confirmed that Wnt signaling was substantially inhibited in the Sulf-2 silenced cells relative to control-treated cells for both BxPC-3 and L3.6sl cells (). Again, BxPC-3 cells showed stronger inhibition (52% with pLV-1413) than the L3.6sl cells (35% inhibition with pLV-1413 or pLV-1143). We determined the effects of Sulf-2 silencing on cell proliferation by measuring the incorporation of 5-bromodeoxyuridine (BrdU) into the cells. There was a 25–30% reduction of cells undergoing S-phase in L3.6sl, BxPC3, and HS766T cells, and only a 5% reduction in CFPAC-1 cells (). Additionally, we performed apoptosis assays by measuring annexin V staining. The Sulf-2 silenced BxPC-3 cells showed an increase in apoptosis of 33%, whereas the L3.6sl cells showed increases of 65% and 79% with two independent shRNAs (). To examine cell growth over time in Sulf-2 silenced cells, we compared growth of cells in which Sulf-2 was silenced with non-transduced parental cells in a mixed culture. In parallel co-cultures, we compared the growth of control shRNA-transduced cells with parental non-transduced cells. For both of the Sulf-2 specific shRNAs, the non-silenced parental L3.6sl cells progressively overtook the silenced cells with time in culture. Similar results were seen with the BxPC-3 cells (). In contrast, there was no change in the ratio of the control-transduced cells to parental cells over time (). Silencing of Sulf-2 inhibits tumor growth in vivo To determine the effects of Sulf-2 silencing on the tumorigenicity of L3.6sl and BxPC-3 cells in vivo, we compared the growth of tumors that formed in immunocompromised mice with or without silencing of Sulf-2. Nude mice (CD-1) were injected subcutaneously with either pLV-ctrl or pLV-1413 transduced cells 1 week after transduction. Tumor size was followed with time by external palpation. At the end of the experiment, animals were sacrificed and tumor weights were measured. As shown in , tumors derived from Sulf-2 silenced cells (L3.6sl or BxPC-3) grew at a markedly slower rate than those derived from the control cells (). The harvested tumors from silenced cells were correspondingly reduced in weight with no overlap of the two groups for either cell line (). The prevailing view in the literature has been that the Sulfs are negative regulators of tumor cell growth. A number of reports demonstrated that over-expression of Sulf-1 [28]– [34] or Sulf-2 [32] in tumor cell lines inhibited growth factor signaling in response to several factors, including FGF-2, HB-EGF, and HGF. Moreover, the tumorigenicity of Sulf-overexpressing cells in immunocompromized mice was diminished [31], [32], [34]. The negative effects of Sulfs on FGF-2 signaling are consistent with the known requirement for 6S on HSPGs in the FGF-2 signaling complex [37]. These cell line findings have led to the suggestion that down-regulation of Sulfs could provide tumor cells with a growth advantage in certain settings. This model may have validity for the significant subset (two-thirds) of ovarian cancer cases [28] and the minor subset (29%) of hepatocellular carcinoma cases [30] in which SULF1 expression is downregulated relative to that in normal tissue. However, the model is problematic for the sizeable subsets of several cancers which show increases in SULF expression. Thus, for example, SULF1 is upregulated in significant subsets of breast cancer [38], pancreatic cancer [31], [39] ( Table 1) lung adenocarcinoma [40] and hepatocellular carcinoma [30], while SULF2 is upregulated in multiple myeloma [32], breast cancer and CNS cancers [41]. To understand the significance of upregulated SULF expression in a cancer, we chose to focus on pancreatic adenocarcinomas because of clear evidence associating this cancer with canonical Wnt signaling, a signaling pathway known to be positively regulated by the Sulfs during development (see above). Consistent with the transcript expression data ( Table 1), we found that both Sulfs were strongly expressed at the protein level by malignant epithelial cells in pancreatic adenocarcinoma. To facilitate investigation of these enzymes in pancreatic cancer, we examined SULF expression in a large panel of pancreatic adenocarcinoma cell lines and found widespread expression, especially of SULF2. We chose 4 lines for study, all of which expressed Sulf-2 protein and one of which expressed both Sulfs. Previous studies have shown that proliferation and survival of 3 of these (BxPC-3, HS766T and L3.6sl) depend on activated Wnt signaling [M. Pasca di Magliano and M. Hebrok, unpublished observations]. We showed that Wnt signaling was markedly inhibited by overexpressing recombinant sFRP-2 in these cell lines. Moreover, overexpression of catalytically inactive Sulf-2 in the same lines resulted in a marked inhibition of Wnt activity, and exposure of the cells to inactive Sulf-2 protein during culture inhibited both Wnt signaling and growth. These results are consistent with Wnt-ligand dependent growth of these cells (“autocrine Wnt signaling”), which is modulated by the extracellular Sulfs. It is plausible that the CFPAC-1 cell line, which was refractory to all of these treatments, carries an activating mutation in downstream elements of the Wnt signaling pathway that would bypass the need for extracellular Wnt ligands and the Sulfs. It should be noted that the Sulfs represent an additional example of an extracellular factor, which modulates Wnt signaling. However, in contrast to the extracellular Wnt antagonists such as DKK1 and sFRPs, which are suppressed in certain tumors, the Sulfs are upregulated in pancreatic adenocarcinomas and exert a positive effect on Wnt signaling. Here we demonstrate that the Sulfs enhance the activity of the Wnt pathway in tumor cells, a function demonstrated previously only in a developmental context. Our results indicate that catalytically inactive Sulf-2 can act as a dominant-negative mutant. There are several plausible mechanisms to explain this effect. One is that inactive Sulf-2 acts as a “substrate trapping mutant” such that it competes with the active enzyme for binding to heparan sulfate substrates, thereby blocking the ability of the enzyme to alter the substrate and modulate Wnt interactions. A second explanation is based on the observation that certain sulfatases (e.g., arylsulfatase A), can form homo-oligomers [42]. The Sulfs have the potential to form multimers due to their predicted coiled-coil structure [22]. Thus, the catalytically inactive protein could interfere with the general activity when incorporated into a multimer. Thirdly, the inactive Sulf might displace the wild-type enzyme from a subdomain in the plasma membrane where it is normally targeted for optimal function. The cell surface associations of QSulf-1 and QSulf -2 are known to require the hydrophilic domains of the molecules, but the molecular details have not been worked out [43]. To rigorously test the involvement of the Sulfs in Wnt signaling and tumor growth, we used lentiviral shRNA systems to silence Sulf-2 expression in four pancreatic adenocarcinoma cell lines. This approach contrasts with previous studies in which function of a Sulf was investigated in cancer cell lines by overexpressing it in cells that lacked it [28]– [34]. Sulf-2 silenced cells (BxPC-3, L3.6sl, HS766T) exhibited a decrease in DNA synthesis and an increase in apoptosis (BxPC-3, L3.6sl). Moreover, the silenced cells exhibited reduced Wnt activity by two criteria. Consistent with these findings, silenced cells showed a marked growth disadvantage in co-cultures with control cells. The dominant negative effects in the co-culture experiments with stably transfected HEK 293T cells () suggest that Sulf-2 can function in trans, at least in the setting of artificial overexpression of the protein. Therefore, one might predict rescue of the silenced cells by the secreted Sulf-2 protein from control cells. We conclude that the rescue effect was at best partial, since the silenced cells grew at a slower rate than the control cells in the mixed culture. The in vitro results were extended into a tumorigenesis model in nude mice by demonstrating that Sulf-2-silenced L3.6sl and BxPC-3 cells formed smaller tumors with time. Our evidence for the involvement of the Sulfs in the growth and tumorigenesis of pancreatic adenocarcinoma cells is most complete for Sulf-2. It remains to be seen what impact silencing Sulf-1 will have on a cell type that expresses this enzyme alone or in combination with Sulf-2 (e.g., HS766T cells). One might predict functional redundancy of the two enzymes based on the ability of either inactive Sulf to exert equivalent dominant negative effects (). Moreover, the two enzymes exhibit indistinguishable enzymatic activities against heparin/heparan sulfate in vitro [22], [43], although there is recent genetic evidence for cooperative activities [26]. The present findings are the first to implicate the Sulfs as positive regulators of growth in a cancer, namely pancreatic tumors that are driven by autocrine Wnt signaling. Further xenograft experiments with cell lines and primary tumor cells, together with studies of mouse models of pancreatic adenocarcinoma [44], are needed to test this proposed role for the Sulfs. Accumulating evidence indicates that a number of other cancers also depend on autocrine Wnt signaling for growth [6]– [8], [15], [45]– [47]. Since SULF upregulation has been found in a number of these cancers, the potential role of these enzymes in enhancing tumorigenesis deserves exploration in these systems. As extracellular enzymes, the Sulfs would be very attractive therapeutics targets for both small molecule and antibody approaches. Constructs Sulf cDNA constructs were cloned in our lab as described [22]. For Sulf-2 siRNA experiments, we used the target region GCTGAAGCTGCATAAGTGC (1413) or GGAGTGGTGGTGTCAATAA (1143) and AACAGTCGCGTTTGCGACTGG as control. The hairpin oligonucleotides were cloned into the plasmids pSico or pLVTHM as described [48], [49]. To activate the shRNA in pSico, transduced BxPC-3 cells were sorted for GFP expression and subsequently transiently transfected with a cre recombinase plasmid to excise the CMV-GFP reporter cassette and thus activate expression of the shRNAs. 10 days after cre-recombinase transfection, cells were sorted for GFP negative cells and analyzed for HSulf-2 expression and used for further experiments. The pPGK-cre-bpa plasmid was generously provided by Dr. M.S. German and the pLVTHM was provided by Dr. S.S. Sidhu. Preparation of Anti-Sulf-1 Polyclonal Antibodies Polyclonal antibodies were produced by ProSci. Rabbits were immunized and purified as described [25] with a peptide, derived from the predicted human Sulf-1 sequence (H1.5: CPKNLDVGNKDGGSYDLHRGO-COOH, where C denotes the cysteine residue added for coupling). Histology and immunoblotting assays Under Committee for Human Experimentation approval (H1060-27616-01), archived formalin-fixed paraffin-embedded tissue blocks were obtained for seven cases of invasive pancreatic adenocarcinoma. Hydrated 4 µm sections were subject to heat induced epitope retrieval (10′ in a pressure cooker) and stained with either purified polyclonal rabbit Ab H1.5 or Ab H2.3. A purified polyclonal rabbit antibody directed to HSVI/II served as a negative control. Antibody binding was visualized by the Dako Envision (+) system (cat #K4011). Areas of invasive adenocarcinoma were identified by architectural features (infiltration and associated desmoplasia) and confirmed by cytologic features (nuclear enlargement, pleomorphism, and hyperchromasia) on H&E-stained sections. Interlobular ducts without any of the above features served as an internal control. Cell lysates were prepared by extraction of washed cells in RIPA buffer (150 mM NaCl, 1% Triton X-100, 0.1% SDS, protease inhibitor cocktail (Roche), 50 mM Tris-HCl pH 7.5 for 20 min on ice. Insoluble material was pelleted by centrifugation for 30 minutes at 21.000 g. For analysis of conditioned medium (CM), the CM was concentrated on a Centricon30 microconcentrator (Millipore Corp.). For extracting nuclear proteins, we used the Compartmental Protein Extraction Kit (Chemicon International/Millipore). Equal protein concentrations were loaded based on quantification with the BCA™ Protein Assay (Pierce, Rockford, IL) following the manufacturer's procedure. Total cell lysates or CM were subjected to SDS-PAGE on 7.5 or 10% polyacrylamide gels (BioRad) blotted to ProBlott™ (Applied Biosystems). Immunoblotting was performed as described [22] with affinity purified rabbit polyclonal antibodies H1.5 for human Sulf-1 and H2.3 or H2.1 for human Sulf-2 [25]. For detection of β-catenin we used anti-active-β-catenin antibody (clone 8E7, Millipore), for histone detection we used anti-Histone H1 (clone AE-4, Millipore). For detection of actin we used the antibody “Actin (I-19)” from Santa Cruz Biotechnology Inc. Cell culture and gene transduction Human pancreatic adenocarcinoma cell lines CFPAC-1, HS766T, L3.6sl and the human embryonic kidney cells HEK 293 were maintained in Dulbecco's modified Eagle's (DMEM) medium supplemented with 10% fetal bovine serum. Human pancreatic adenocarcinoma cell line BxPC-3 was maintained in RPMI medium supplemented with 10% fetal bovine serum. Sulf2 and S2ΔCC expressing HEK 293 cells were generated and grown as described [25]. We have previously verified the elimination of enzymatic activity in the S2ΔCC mutant [25]. We employed the same strategy for achieving stable expression of Sulf-1 and catalytically inactivated Sulf-1 in HEK 293 cells. For transient transfections, Fugene (Roche) or for Cre transfection the Basic Nucleofector Kit for Primary Mammalian Epithelial Cells (Amaxa) was used. Lentivirus production and infection was done as described [48], [49]. To generate pSico transduced cell lines 15–20 GFP positive colonies were picked and co-cultured. 10 days after Cre-transfection cell populations were sorted by FACS for GFP negative cells. NIH 3T3 fibroblast cells, expressing Wnts were generously provided by Dr. A. Kispert, Germany. RT-PCR and Data mining For analyzing Sulf expression patterns in published gene microarray studies, we used the oncomine database ( www.oncomine.org) and http://source.Stanford.edu. Total RNAs were extracted from cells using Trizol (Invitrogen) and cDNA was generated using Superscript II Reverse Transcriptase (Invitrogen). For RT-PCR the following primer combinations were used: Sulf-1 forward: 5′-CTCACAGTCCGGCAGAGCACGCGGAAC-3′, and reverse: 5′-CACGGCGTTGCTGCTATCTGCCAGCATCC-3′. For Sulf-2, the following primers were used: forward 5′-GAAAAGAGGCAGATTCACGTCGTTTCCAG-3′ and reverse 5′-ATCTGGTGCTTCTTTTGGGATGCGGGAG-3′. SYBR Green real time PCR was done, using the primer pairs: Sulf1F: 5′-TTGAAGAGAGCATAATTGGAATGG-3′, Sulf1R: 5′-CTGCATGTCATTTGCCA AGTTT-3′ and Sulf2F: 5′-C CTCTTCCCAAACGCATCTC-3′ and 5′-GCGCATGAT CCAGTGTTTGT-3′. The conditions for denaturing, annealing and extension of the template cDNA were as follows: 94°C for 30 sec, 55°C for 30 sec and 72°C for 1 min for 35 cycles. PCR products were separated by electrophoresis on 2% agarose gels and visualized with ethidium bromide. Luciferase reporter assays Cells transfected with either TOPflash or FOPflash and Renilla-Luciferase control plasmid (Promega). After 48 hrs cells analyzed utilizing the Dual Luciferase Reporter Assay system (Promega). Luciferase activity was normalized to control Renilla-Luciferase activity. To determine Sulf influence on Wnt signaling in HEK 293T cells, cells were transfected with TOP/FOPflash and Renilla control plasmid and incubated with CM from Wnt1 or Wnt4 transfected 3T3 human fibroblasts for 24 hours. Co-culture experiment Co-culture experiments were performed in transwell plates with 24 well inserts with 5 µm pore size (Corning Incorporated). HEK293T cells were plated in the wells as feeder layer and one day later 1–2×103 cells of the pancreatic adenocarcinoma cell lines were plated in the inserts. BrdU incorporation assay BrdU incorporation was measured by flow cytometry, using the APC BrdU Flow Kit (BD Biosciences), pulsing cells for one hour. Cell Apoptosis assay Cell apoptosis was detected using the Annexin V PE apoptosis detection kit (BD Biosciences) following the manufacturer's protocol. Tumorigenicity assays: BxPC-3 cells, transduced with either control or Sulf-2 shRNA were subcutaneously injected in 6 week nude mice at 5×10 6 cells per site. Tumor growth was monitored every two to three days [7]. Figure S1 Sulf promotion of Wnt signaling in a reconstituted system. HEK 293T cells, stably transfected with either Sulf-1, Sulf-2 or a control vector, were co-cultured alone or with NIH 3T3 cells that were stably transfected with either Wnt1, Wnt2 or lacZ control. Wnt signaling in the various HEK 293T cells was measured by TCF-luciferase reporter activity. Values are normalized to control HEK 293T cells cultured alone. (0.49 MB EPS) We thank Dr. Bioa He, UCSF the sFRP-2 cDNA. We are grateful to Dr. Zena Werb of the Dept of Anatomy at UCSF for critically reading the manuscript and providing advice during the course of the study. We thank Durwin Tsay and Amy Heidersbach for assistance in preparation of the lentivirus. We are grateful to Dr. Megumi Morimoto-Tomita for her help in preparing and characterizing the Sulf-1 antibody. 1. Laheru D, Jaffee EM. Immunotherapy for pancreatic cancer - science driving clinical progress. Nat Rev Cancer. 2005;5:459–467. [PubMed] 2. Pasca di Magliano M, Hebrok M. Hedgehog signalling in cancer formation and maintenance. Nat Rev Cancer. 2003;3:903–911. [PubMed] 3. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature. 2005;434:843–850. [PubMed] 4. Berman DM, Karhadkar SS, Maitra A, Montes De Oca R, Gerstenblith MR, et al. Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature. 2003;425:846–851. [PubMed] 5. Thayer SP, di Magliano MP, Heiser PW, Nielsen CM, Roberts DJ, et al. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature. 2003;425:851–856. [PubMed] 6. Nusse R, Varmus HE. Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell. 1982;31:99–109. [PubMed] 7. Bafico A, Liu G, Goldin L, Harris V, Aaronson SA. An autocrine mechanism for constitutive Wnt pathway activation in human cancer cells. Cancer Cell. 2004;6:497–506. [PubMed] 8. Derksen PW, Tjin E, Meijer HP, Klok MD, MacGillavry HD, et al. Illegitimate WNT signaling promotes proliferation of multiple myeloma cells. Proc Natl Acad Sci U S A. 2004;101:6122–6127. [PubMed] 9. Zeng G, Germinaro M, Micsenyi A, Monga NK, Bell A, et al. Aberrant Wnt/beta-catenin signaling in pancreatic adenocarcinoma. Neoplasia. 2006;8:279–289. [PubMed] 10. Lowy AM, Fenoglio-Preiser C, Kim OJ, Kordich J, Gomez A, et al. Dysregulation of beta-catenin expression correlates with tumor differentiation in pancreatic duct adenocarcinoma. Ann Surg Oncol. 2003;10:284–290. [PubMed] 11. Chada S, Bocangel D, Ramesh R, Grimm EA, Mumm JB, et al. mda-7/IL24 kills pancreatic cancer cells by inhibition of the Wnt/PI3K signaling pathways: identification of IL-20 receptor-mediated bystander activity against pancreatic cancer. Mol Ther. 2005;11:724–733. [PubMed] 12. Kawano Y, Kypta R. Secreted antagonists of the Wnt signalling pathway. J Cell Sci. 2003;116:2627–2634. [PubMed] 13. Lin X. Functions of heparan sulfate proteoglycans in cell signaling during development. Development. 2004;131:6009–6021. [PubMed] 14. Alexander CM, Reichsman F, Hinkes MT, Lincecum J, Becker KA, et al. Syndecan-1 is required for Wnt-1-induced mammary tumorigenesis in mice. Nat Genet. 2000;25:329–332. [PubMed] 15. Capurro MI, Xiang YY, Lobe C, Filmus J. Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res. 2005;65:6245–6254. [PubMed] 16. Esko JD, Lindahl U. Molecular diversity of heparan sulfate. J Clin Invest. 2001;108:169–173. [PubMed] 17. Gallagher JT. Heparan sulfate: growth control with a restricted sequence menu. J Clin Invest. 2001;108:357–361. [PubMed] 18. Uchimura K, Morimoto-Tomita M, Bistrup A, Li J, Lyon M, et al. HSulf-2, an extracellular endoglucosamine-6-sulfatase, selectively mobilizes heparin-bound growth factors and chemokines: effects on VEGF, FGF-1, and SDF-1. BMC Biochem. 2006;7:2. [PubMed] 19. Ai X, Do AT, Lozynska O, Kusche-Gullberg M, Lindahl U, et al. QSulf1 remodels the 6-O sulfation states of cell surface heparan sulfate proteoglycans to promote Wnt signaling. J Cell Biol. 2003;162:341–351. [PubMed] 20. Dhoot GK, Gustafsson MK, Ai X, Sun W, Standiford DM, et al. Regulation of Wnt signaling and embryo patterning by an extracellular sulfatase. Science. 2001;293:1663–1666. [PubMed] 21. Ohto T, Uchida H, Yamazaki H, Keino-Masu K, Matsui A, et al. Identification of a novel nonlysosomal sulphatase expressed in the floor plate, choroid plexus and cartilage. Genes Cells. 2002;7:173–185. [PubMed] 22. Morimoto-Tomita M, Uchimura K, Werb Z, Hemmerich S, Rosen SD. Cloning and characterization of two extracellular heparin-degrading endosulfatases in mice and humans. J Biol Chem. 2002;277:49175–49185. [PubMed] 23. Viviano BL, Paine-Saunders S, Gasiunas N, Gallagher J, Saunders S. Domain specific modification of HS by Qsulf1 modulates the binding of the BMP antagonist Noggin. J Biol Chem. 2003;279:5604–5611. [PubMed] 24. Kakinuma Y, Saito F, Ohsawa S, Furuichi T, Miura M. A sulfatase regulating the migratory potency of oligodendrocyte progenitor cells through tyrosine phosphorylation of beta-catenin. J Neurosci Res. 2004;77:653–661. [PubMed] 25. Morimoto-Tomita M, Uchimura K, Bistrup A, Lum DH, Egeblad M, et al. Sulf-2, a proangiogenic heparan sulfate endosulfatase, is upregulated in breast cancer. Neoplasia. 2005;7:1001–1010. [PubMed] 26. Lamanna WC, Baldwin RJ, Padva M, Kalus I, Ten Dam G, et al. Heparan sulfate 6-O-endosulfatases: discrete in vivo activities and functional co-operativity. Biochem J. 2006;400:63–73. [PubMed] 27. Lum DH, Tan JH, Rosen SD, Werb Z. Gene trap disruption of the mouse heparan sulfate 6-O endosulfatase, Sulf2. Mol Cell Biol. 2006;27:678–688. [PubMed] 28. Lai J, Chien J, Staub J, Avula R, Greene EL, et al. Loss of HSulf-1 up-regulates heparin-binding growth factor signaling in cancer. J Biol Chem. 2003;278:23107–23117. [PubMed] 29. Lai JP, Chien J, Strome SE, Staub J, Montoya DP, et al. HSulf-1 modulates HGF-mediated tumor cell invasion and signaling in head and neck squamous carcinoma. Oncogene. 2004;23:1439–1447. [PubMed] 30. Lai JP, Chien JR, Moser DR, Staub JK, Aderca I, et al. hSulf1 Sulfatase promotes apoptosis of hepatocellular cancer cells by decreasing heparin-binding growth factor signaling. Gastroenterology. 2004;126:231–248. [PubMed] 31. Li J, Kleeff J, Abiatari I, Kayed H, Giese NA, et al. Enhanced levels of Hsulf-1 interfere with heparin-binding growth factor signaling in pancreatic cancer. Mol Cancer. 2005;4:14. [PubMed] 32. Dai Y, Yang Y, MacLeod V, Yue X, Rapraeger AC, et al. HSulf-1 and HSulf-2 are potent inhibitors of myeloma tumor growth in vivo. J Biol Chem. 2005;280:40066–40073. [PubMed] 33. Lai JP, Yu C, Moser CD, Aderca I, Han T, et al. SULF1 inhibits tumor growth and potentiates the effects of histone deacetylase inhibitors in hepatocellular carcinoma. Gastroenterology. 2006;130:2130–2144. [PubMed] 34. Narita K, Staub J, Chien J, Meyer K, Bauer M, et al. HSulf-1 inhibits angiogenesis and tumorigenesis in vivo. Cancer Res. 2006;66:6025–6032. [PubMed] 35. Heller RS, Klein T, Ling Z, Heimberg H, Katoh M, et al. Expression of Wnt, Frizzled, sFRP, and DKK genes in adult human pancreas. Gene Expr. 2003;11:141–147. [PubMed] 36. Galli LM, Barnes T, Cheng T, Acosta L, Anglade A, et al. Differential inhibition of Wnt-3a by Sfrp-1, Sfrp-2, and Sfrp-3. Dev Dyn. 2006;235:681–690. [PubMed] 37. Kreuger J, Salmivirta M, Sturiale L, Gimenez-Gallego G, Lindahl U. Sequence analysis of heparan sulfate epitopes with graded affinities for fibroblast growth factors 1 and 2. J Biol Chem. 2001;276:30744–30752. [PubMed] 38. Grigoriadis A, Mackay A, Reis-Filho JS, Steele D, Iseli C, et al. Establishment of the epithelial-specific transcriptome of normal and malignant human breast cells based on MPSS and array expression data. Breast Cancer Res. 2006;8:R56. [PubMed] 39. Iacobuzio-Donahue CA, Maitra A, Olsen M, Lowe AW, van Heek NT, et al. Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. Am J Pathol. 2003;162:1151–1162. [PubMed] 40. Bhattacharjee A, Richards WG, Staunton J, Li C, Monti S, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A. 2001;98:13790–13795. [PubMed] 41. Morimoto-Tomita MU, Rosen Kenji;, Steven D. Novel extracellular sulfatases: potential roles in cancer. Trends in Glycosciences and Glycotechnology. 2003;15:159–164. 42. Marcao A, Azevedo JE, Gieselmann V, Sa Miranda MC. Oligomerization capacity of two arylsulfatase A mutants: C300F and P425T. Biochem Biophys Res Commun. 2003;306:293–297. [PubMed] 43. Ai X, Do AT, Kusche-Gullberg M, Lindahl U, Lu K, et al. Substrate specificity and domain functions of extracellular heparan sulfate 6-O-endosulfatases, QSulf1 and QSulf2. J Biol Chem. 2006;281:4969–4976. [PubMed] 44. Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell. 2005;7:469–483. [PubMed] 45. He B, Lee AY, Dadfarmay S, You L, Xu Z, et al. Secreted frizzled-related protein 4 is silenced by hypermethylation and induces apoptosis in beta-catenin-deficient human mesothelioma cells. Cancer Res. 2005;65:743–748. [PubMed] 46. Mazieres J, He B, You L, Xu Z, Lee AY, et al. Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer. Cancer Res. 2004;64:4717–4720. [PubMed] 47. You L, He B, Xu Z, Uematsu K, Mazieres J, et al. Inhibition of Wnt-2-mediated signaling induces programmed cell death in non-small-cell lung cancer cells. Oncogene. 2004;23:6170–6174. [PubMed] 48. Ventura A, Meissner A, Dillon CP, McManus M, Sharp PA, et al. Cre-lox-regulated conditional RNA interference from transgenes. Proc Natl Acad Sci U S A. 2004;101:10380–10385. [PubMed] 49. Wiznerowicz M, Trono D. Conditional suppression of cellular genes: lentivirus vector-mediated drug-inducible RNA interference. J Virol. 2003;77:8957–8961. [PubMed] 50. Su AI, Welsh JB, Sapinoso LM, Kern SG, Dimitrov P, et al. Molecular classification of human carcinomas by use of gene expression signatures. Cancer Res. 2001;61:7388–7393. [PubMed]
|
This article has been 
